JANX Janux Therapeutics, Inc.

NASDAQ
$16.30

Janux Therapeutics, Inc. (JANX) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is a loss of $0.45 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +3.6% since its last earnings release on August 6, 2026.

Janux Therapeutics, Inc. Missed Consensus Estimates
Thursday, August 6, 2026 · 4:02 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 4:00 PM ET
Earnings Whisper
-
vs ($0.45)
Rev est $6.93M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $17.71

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Janux Therapeutics, Inc.

Janux is a clinical-stage biopharmaceutical company developing next-generation bispecific immunotherapies with the goal of fighting cancers by killing tumor cells while allowing healthy tissues to remain unharmed.

Sector

Healthcare

Industry

Biotechnology

Held By 4 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.